PPP1R1B and neoplasm: Mice challenged with HCC827GR cells with DARPP-32 stably silenced by shRNA show decreased tumor growth when treated every other day with gefitinib relative to vehicle controls (Fig. 7b and Supplementary Fig. 13a).